CareDx Inc Total Liabilities
CareDx Inc total liabilities. Based on the latest financial reports, CareDx Inc (CDNA) has total liabilities worth $107.39 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CareDx Inc (CDNA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CareDx Inc (2012–2025)
Total liabilities of CareDx Inc from 2012 to 2025. This chart illustrates how CareDx Inc's total liabilities have evolved over time, based on quarterly financial data. Explore CareDx Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
CareDx Inc Competitors by Total Liabilities
The table below lists competitors of CareDx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Bright Power Semiconductor
SHG:688368
|
China | CN¥2.56 Billion |
|
Beijing Easpring Material Tech
SHE:300073
|
China | CN¥4.81 Billion |
|
GOLDEN AGRI-RES ADR/100
F:4G3
|
Germany | €5.66 Billion |
|
Zhejiang Wanfeng Auto Wheel Co Ltd
SHE:002085
|
China | CN¥8.18 Billion |
|
American Eagle Outfitters Inc
NYSE:AEO
|
USA | $2.35 Billion |
|
Danaos Corporation
NYSE:DAC
|
USA | $1.39 Billion |
|
Sichuan Hebang Biotechnology Co Ltd
SHG:603077
|
China | CN¥10.30 Billion |
|
Shanxi Taigang Stainless Steel Co Ltd
SHE:000825
|
China | CN¥28.25 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down CareDx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is CareDx Inc's balance sheet.
Liquidity & Leverage Metrics
CareDx Inc Total Liabilities Ratios Explained
CareDx Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CareDx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CareDx Inc (2012–2025)
The table below shows the annual total liabilities of CareDx Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $110.13 Million | -2.21% |
| 2024-12-31 | $112.62 Million | -45.20% |
| 2023-12-31 | $205.50 Million | +83.35% |
| 2022-12-31 | $112.08 Million | +11.25% |
| 2021-12-31 | $100.75 Million | +10.91% |
| 2020-12-31 | $90.83 Million | +72.24% |
| 2019-12-31 | $52.74 Million | +51.68% |
| 2018-12-31 | $34.77 Million | -61.16% |
| 2017-12-31 | $89.52 Million | +57.14% |
| 2016-12-31 | $56.97 Million | +117.90% |
| 2015-12-31 | $26.14 Million | +31.75% |
| 2014-12-31 | $19.84 Million | -87.64% |
| 2013-12-31 | $160.55 Million | +2.21% |
| 2012-12-31 | $157.08 Million | -- |
About CareDx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart tr… Read more